
<DOC>
<DOCNO>WT02-B24-138</DOCNO>
<DOCOLDNO>IA089-000954-B013-358</DOCOLDNO>
<DOCHDR>
http://www.ldanatl.org:80/articles/seab/weinberg/table11.html 206.86.190.251 19970109190054 text/html 10052
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 19:00:58 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 9870
Last-modified: Fri, 11 Oct 1996 05:38:57 GMT
</DOCHDR>
<html>
<head>
<title>Table 11. Antidepressant Pharmacotherapy</title>
</head>
<body bgcolor="#FFFFFF">
<h2 align=center> Table 11. Antidepressant Pharmacotherapy</h2>


<TABLE border=1>
<tr><td valign=top rowspan=18><b>Amitriptyline</b></td>

    <td valign=top rowspan=2>Dosage Range</td>
    <td>Children 1-3 mg/kg/d (up  to 5 mg/kg/d if monitored)</td></tr>
<tr><td>Adolescents 110-200</td></tr>

<tr><td valign=top>Serum level (mg/ml)</td>
    <td>100-250 sum of amitriptyline plus nortriptyline)</td></tr>

<tr><td valign=top rowspan=2>Indications</td>
    <td>Primary drug of choice for depression in non-obese
        preadolescents, or underweight adolescents, with a history
        of "pure familial" type of affective disorder</td></tr>
<tr><td>Tertiary drug for depression in adolescents or if family 
        history of "depressive spectrum biogeny"</td></tr>

<tr><td rowspan=4 valign=top>Contraindications</td>
    <td>Obesity</td></tr>
<tr><td>Excessive daytime sleepiness </td></tr>
<tr><td>History of paroxysmal atrial tachycardia other cardiac
         conduction disturbances</td></tr>
<tr><td>Liver or renal disease unless dose and serum levels can be
        closely monitored</td>

<tr><td valign=top rowspan=9>Potential Adverse Effects</td>
    <td>Induction or promotion of mania</td></tr>
<tr><td>Atropinic side effects</td></tr>
<tr><td>Mild tremor</td></tr>
<tr><td>Worsening of depressive symptoms</td></tr>
<tr><td>Increased appetite and excess</td></tr>
<tr><td>Excessive daytime sleepiness</td></tr>
<tr><td>Rash</td></tr>
<tr><td>EKG evidence of cardiac conduction changes + </td></tr>
<tr><td>Hypertension<br><br></td></tr>


<tr><td valign=top rowspan=8><b>Nortriptyline</b><br>
     (A metabolite<br>of amitriptyline)&nbsp;</td>
     <td valign=top rowspan=2>Dosage Range</td>
     <td>Children 1-3 mg/kg/d</td></tr>
<tr><td>Adolescents 50-150 mg</td></tr>
<tr><td valign=top>Serum level (mg/ml)</td>
    <td>50-150</td></tr>
<tr><td valign=top>Indications</td>
    <td>Secondary drug for depression in children and
        adolescents</td></tr>
<tr><td rowspan=2 valign=top>Contraindications</td>
    <td>History of paroxysmal atrial tachycardia or other 
        cardiac conduction disturbances</td></tr>
<tr><td>Liver or renal disease unless dose and serum levels 
        can be closely monitored</td></tr>
<tr><td valign=top rowspan=2>Potential Adverse Effects</td>
    <td>Same as amitriptyline except with less effect on appetite 
        and weight</td></tr>
<tr><td>"Therapeutic window" in which sub-therapeutic dosages
        worsen<br><br> </td></tr>


<tr><td valign=top rowspan=16><b>Imipramine</b></td>

    <td valign=top rowspan=2>Dosage Range</td>
    <td>Children 1-3 mg/kg/d (up to 5 mg/kg/d if monitored)</td></tr>
<tr><td> Adolescents 100-200 mg/d</td></tr>

<tr><td valign=top >Serum level (mg/ml)</td>
    <td>150-250 (sum of imipramine plus desipramine)</td></tr>

<tr><td valign=top>Indications</td>
    <td>Primary drug of choice for depression in adolescents, 
        obese children, or with a family history of "depressive 
        spectrum biogeny"</td></tr>

<tr><td rowspan=3 valign=top>Contraindications</td>
    <td>Significantly under-weight or with anorexia</td></tr>
<tr><td>History of paroxysmal atrial tachycardia or other 
        cardiac conduction disturbance</td></tr>
<tr><td>Liver or renal disease unless dose and serum levels 
        can be closely monitored</td></tr>

<tr><td rowspan=9 valign=top>Potential Adverse Effects</td>
    <td>Induction or promotion of mania</td></tr>
<tr><td>Atropinic side effects</td></tr>
<tr><td>Mild tremor</td></tr>
<tr><td>Worsening of depressive symptoms</td></tr>
<tr><td>Decreased appetite and excess weight loss</td></tr>
<tr><td>Excessive daytime sleepiness</td></tr>
<tr><td>Rash</td></tr>
<tr><td>EKG evidence of cardiac conduction changes</td></tr>
<tr><td>Hypertension</td></tr>


<tr><td valign=top rowspan=7><b>Desipramine<br>(a metabolite<br>
         of imipramine)</td>
    <td valign=top rowspan=2>Dosage Range</td>
    <td>Children 1-3 mg/kg/d (up to 5 mg/kg/d if monitored)</td></tr>
<tr><td>Adolescents 100-200 mg/d</td></tr>
<tr><td valign=top >Serum level (mg/ml)</td>
     <td>50-300</td></tr>
<tr><td valign=top rowspan=2>Indications</td>
    <td>Primary or secondary drug of choice for depression in children
        and adolescents with excessive daytime sleepiness</td></tr>
<tr><td>Secondary drug for depression in adolescents, obese children, 
        or with a family history of "depressive spectrum 
        biogeny"</td></tr>
<tr><td valign=top>Contraindications</td>
    <td>Same as nortriptyline</td></tr>
<tr><td valign=top>Potential Adverse Effects</td>
    <td>Same as imipramine, plus insomnia</td></tr>


<tr><td valign=top rowspan=7><b>Doxepin</b></td>

    <td valign=top rowspan=2>Dosage Range</td>
    <td>Children 1-3 mg/kg/d</td>
<tr><td>Adolescents l00-200  mg/d</td></tr>
<tr><td valign=top>Serum level (mg/ml)</td>
    <td>75-200</td></tr>
<tr><td valign=top rowspan=2>Indications</td>
    <td>Primary drug of choice for depression in non-obese 
        children and adolescents with prominent anxiety, phobias, 
        and somatic symptoms</td></tr>
<tr><td>Tertiary drug for depression in  non-obese children and
        adolescents without excessive daytime sleepiness</td></tr>
<tr><td valign=top>Contraindications</td>
    <td>Same as amitriptyline</td></tr>
<tr><td valign=top>Potential Adverse Effects</td>
    <td>Same as amitriptyline, except infrequently induces 
        or promotes mania</td></tr>



<tr><td valign=top rowspan=14><b>Protriptyline</b></td>
    <td valign=top rowspan=2>Dosage Range</td>
    <td>children 5-10 mg bid or tid*</td></tr>
<tr><td>Adolescents 5-15 mg bid or tid*</td></tr>

<tr><td valign=top>Serum level (mg/ml)</td>
    <td>70-260</td></tr>
<tr><td valign=top>Indications</td>
    <td>Secondary drug for depression in association with 
        excessive daytime sleepiness (the primary disorder 
        of vigilance)</td> 

<tr><td valign=top>Contraindications</td>
    <td>Same as nortriptyline</td></tr>

<tr><td valign=top rowspan=9>Potential Adverse Effects </td>
    <td>Induction or promotion of mania</td></tr>
<tr><td>Atropinic side effects</td></tr>
<tr><td>Mild tremor</td></tr>
<tr><td>Worsening of depressive symptoms</td></tr>
<tr><td>Decreased appetite and excess weight loss </td></tr>
<tr><td>Insomnia and hyperalertness</td></tr>
<tr><td>Rash</td></tr>
<tr><td>EKG evidence of cardiac conduction changes + </td></tr>
<tr><td>Hypertension</td></tr>


<tr><td valign=top rowspan=5><b>Trazodone</b></td> 
    <td valign=top>Dosage Range</td>
    <td>Adolescents 50-600 mg/d</td></tr>  
<tr><td valign=top>Serum level (mg/ml)</td>
    <td>800-1600</td>
<tr><td valign=top>Indications</td>
    <td>Alternate drug for depression in non-obese 
        individuals or without excessive daytime sleepiness</td></tr>
<tr><td valign=top>Contraindications</td>
    <td>Same as amitriptyline</td></tr>
<tr><td valign=top>Potential Adverse Effects</td>
    <td>Same as amitriptyline, plus priapism</td></tr>


<tr><td valign=top rowspan=5><b>Maprotiline</b></td>  
    <td valign=top>Dosage Range</td>
    <td>Adolescents 75-300 mg/d</td></tr>
<tr><td valign=top>Serum level (mg/ml)</td>
    <td>200-600</td></tr>
<tr><td valign=top>Indications</td>
    <td>Alternate drug for depression in obese individuals 
        or with excessive daytime sleepiness</td></tr>
<tr><td valign=top>Contraindications</td>
    <td>Same as imipramine</td></tr>
<tr><td valign=top>Potential Adverse Effects </td>
    <td>Same as imipramine, plus insomnia</td></tr>


<tr><td valign=top rowspan=10><b>Fluoxetine</b></td>
    <td valign=top rowspan=2>Dosage Range</td>
    <td>Children 20 mg qam</td>
<tr><td>Adolescents 20-40 mg bid*</td></tr>
<tr><td valign=top>Serum level (mg/ml)</td>
    <td>100-900 (combined)</td></tr>
<tr><td valign=top>Indications</td>
    <td>Alternate drug for depression, particularly in 
        obese individuals or with excessive daytime  
        sleepiness</td></tr>
<tr><td valign=top>Contraindications</td>
    <td>Same as imipramine</td></tr>
<tr><td valign=top rowspan=5>Potential Adverse Effects</td>
     <td>Decreased appetite and excess weight loss </td></tr>
<tr><td>Confusion </td></tr>
<tr><td>Incoordination </td></tr>
<tr><td>Insomnia </td></tr>
<tr><td>Induction or promotion of mania</td></tr>


<tr><td valign=top rowspan=5><b>Paraxotine HCl</b></td>
    <td valign=top>Dosage Range</td>
    <td>10-40 mgms qam</td></tr>
<tr><td valign=top>Serum level (mg/ml)</td>
    <td>86 +/- 61</td></tr>
<tr><td valign=top>Indications</td>
     <td>Same as fluoxetine</td></tr>
<tr><td valign=top>Contraindications</td>
    <td>Same as fluoxetine</td></tr>
<tr><td valign=top>Potential Adverse Effects</td>
    <td>Same as fluoxetine</td></tr>

<tr><td valign=top rowspan=5><b>Sertraline HCl</b></td>
    <td valign=top>Dosage Range</td>
    <td>50-100 mgms qam</td></tr>
<tr><td valign=top>Serum level (mg/ml)</td>
    <td>30-200</td></tr>
<tr><td valign=top>Indications</td>
     <td>Same as fluoxetine</td></tr>
<tr><td valign=top>Contraindications</td>
    <td>Same as fluoxetine</td></tr>
<tr><td valign=top>Potential Adverse Effects</td>
    <td>Same as fluoxetine</td></tr>

</table>

<p>* Last dose should not be given after 4 pm<br>
+ EKG = electrocardiogram
<hr>
<font SIZE="-1">Adapted from Brumback RA, Weinberg WA: Pediatric
behavioral neurology: An update on the neurologic aspects of depression,
hyperactivity, and learning disabilities. <i>Neurol Clin</i> 8:677-703,
1990 and adapted from Levy HB. Harner CR. Weinberg WA: A practical
approach to children failing in school.<i> Pediatr Clin North Am</i>
39:895-928, 1992</font>

<p align=center>Back to <a href="">Depression & Other Affective
Illnesses</a>

</body>
<html>
</DOC>